Literature DB >> 24393484

Central role of interferon-beta in thymic events leading to myasthenia gravis.

Perrine Cufi1, Nadine Dragin1, Nathalie Ruhlmann2, Julia Miriam Weiss1, Elie Fadel3, Alain Serraf4, Sonia Berrih-Aknin1, Rozen Le Panse5.   

Abstract

The thymus plays a primary role in early-onset Myasthenia Gravis (MG) mediated by anti-acetylcholine receptor (AChR) antibodies. As we recently showed an inflammatory and anti-viral signature in MG thymuses, we investigated in detail the contribution of interferon (IFN)-I and IFN-III subtypes in thymic changes associated with MG. We showed that IFN-I and IFN-III subtypes, but especially IFN-β, induced specifically α-AChR expression in thymic epithelial cells (TECs). We also demonstrated that IFN-β increased TEC death and the uptake of TEC proteins by dendritic cells. In parallel, we showed that IFN-β increased the expression of the chemokines CXCL13 and CCL21 by TECs and lymphatic endothelial cells, respectively. These two chemokines are involved in germinal center (GC) development and overexpressed in MG thymus with follicular hyperplasia. We also demonstrated that the B-cell activating factor (BAFF), which favors autoreactive B-cells, was overexpressed by TECs in MG thymus and was also induced by IFN-β in TEC cultures. Some of IFN-β effects were down-regulated when cell cultures were treated with glucocorticoids, a treatment widely used in MG patients that decreases the number of thymic GCs. Similar changes were observed in vivo. The injections of Poly(I:C) to C57BL/6 mice triggered a thymic overexpression of IFN-β and IFN-α2 associated with increased expressions of CXCL13, CCL21, BAFF, and favored the recruitment of B cells. These changes were not observed in the thymus of IFN-I receptor KO mice injected with Poly(I:C), even if IFN-β and IFN-α2 were overexpressed. Altogether, these results demonstrate that IFN-β could play a central role in thymic events leading to MG by triggering the overexpression of α-AChR probably leading to thymic DC autosensitization, the abnormal recruitment of peripheral cells and GC formation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemokines; Germinal centers; Glucocorticoids; Interferon; Thymus; Virus

Mesh:

Substances:

Year:  2014        PMID: 24393484     DOI: 10.1016/j.jaut.2013.12.016

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  23 in total

1.  BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells.

Authors:  Marta Epeldegui; Bianca Blom; Christel H Uittenbogaart
Journal:  Eur J Immunol       Date:  2014-12-16       Impact factor: 5.532

Review 2.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 3.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

Review 4.  Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis.

Authors:  Jinjung Choi; Carlo Selmi; Patrick S C Leung; Thomas P Kenny; Tania Roskams; M Eric Gershwin
Journal:  Expert Rev Clin Immunol       Date:  2016-02-25       Impact factor: 4.473

5.  A Systematic Review of the Potential Implication of Infectious Agents in Myasthenia Gravis.

Authors:  Victoria Leopardi; Yu-Mei Chang; Andrew Pham; Jie Luo; Oliver A Garden
Journal:  Front Neurol       Date:  2021-06-14       Impact factor: 4.003

Review 6.  Roles of cytokines and T cells in the pathogenesis of myasthenia gravis.

Authors:  A Uzawa; S Kuwabara; S Suzuki; T Imai; H Murai; Y Ozawa; M Yasuda; Y Nagane; K Utsugisawa
Journal:  Clin Exp Immunol       Date:  2020-12-03       Impact factor: 5.732

7.  Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes.

Authors:  ZhaoHui Luo; Ye Li; XiaoFang Liu; MengChuan Luo; LiQun Xu; YueBei Luo; Bo Xiao; Huan Yang
Journal:  BMC Med Genomics       Date:  2015-03-18       Impact factor: 3.063

8.  Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13.

Authors:  Nilufer Esen; Emily K Rainey-Barger; Amanda K Huber; Pennelope K Blakely; David N Irani
Journal:  Glia       Date:  2014-05-14       Impact factor: 7.452

9.  Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis.

Authors:  Julia Miriam Weiss; Marieke Robinet; Revital Aricha; Perrine Cufi; Bérengère Villeret; Frida Lantner; Idit Shachar; Sara Fuchs; Miriam C Souroujon; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Oncotarget       Date:  2016-02-16

10.  Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report.

Authors:  Su Jung Baik; Tae Hun Kim; Hye In Kim; Jeong Yeon Rhie
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.